Nieuws en video's - CLOVIS ONCOLOGY INC.

Thinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings? PR Newswire NEW YORK, Dec. 12, 2022 NEW YORK , Dec. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, BAC, RIVN, RENT, and VIPS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CLVS:...

Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell...

Thinking about buying stock in Pineapple Energy, Nio, SoFi Technologies, Clovis Oncology, or Rivian Automotive? PR Newswire NEW YORK, Nov. 15, 2022 NEW YORK , Nov. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PEGY, NIO, SOFI, CLVS, and RIVN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. PEGY:...

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)” is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and...

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35 th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 ( 177 Lu-FAP-2286). Overall, in eleven patients treated in the first...

Thinking about buying stock in Myovant Sciences, Clovis Oncology, FingerMotion, LogicBio Therapeutics, or Amplify Energy? PR Newswire NEW YORK, Oct. 3, 2022 NEW YORK , Oct. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYOV, CLVS, FNGR, LOGC, and AMPY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. MYOV:...

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide. Benefit was observed in both primary...

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 ( 177 Lu) n.c.a. for use in the clinical development of FAP-2286, Clovis’ fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the first peptide-targeted radionuclide therapeutic (PTRT) candidate directed against fibroblast activation protein undergoing clinical testing and is...

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that it has submitted a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) and a Type II variation with the European Medicines Agency (EMA) for approval of Rubraca ® (rucaparib) as first-line maintenance treatment for women with advanced ovarian cancer regardless of biomarker status who have responded to first-line platinum-based chemotherapy. The Company believes that the encouraging PFS results, the...

Thinking about buying stock in Regulus Therapeutics, Nio, AMC Entertainment, Carvana, or Clovis Oncology? PR Newswire NEW YORK, Sept. 12, 2022 NEW YORK , Sept. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RGLS, NIO, AMC, CVNA, and CLVS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. RGLS:...

Clovis Oncology, Inc. (NASDAQ: CLVS), today announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO). These data showed that Rubraca as first-line maintenance treatment improved progression-free survival (PFS) versus placebo across disease risk subgroups including surgical outcome, response to first-line chemotherapy, and additional analyses in other subgroups. The data were presented by Rebecca...

Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2022, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook. “We achieved a key milestone in the second quarter, with the presentations of the first clinical data from the LuMIERE trial of FAP-2286 and from the ongoing imaging-only investigator-initiated study. In addition to seeing the first evidence of safety and clinical activity, these...

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis’ results and business outlook in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology...

Thinking about buying stock in Aprea Therapeutics, Dermata Therapeutics, Seres Therapeutics, Avadel Pharmaceuticals, or Clovis Oncology? PR Newswire NEW YORK, July 8, 2022 NEW YORK , July 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRE, DRMA, MCRB, AVDL, and CLVS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. APRE:...

Thinking about buying stock in Axsome Therapeutics, Nio, VEON, United Airlines, or Clovis Oncology? PR Newswire NEW YORK, June 30, 2022 NEW YORK , June 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, NIO, VEON, UAL, and CLVS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AXSM:...

Thinking about buying stock in Energy Focus, Ford Motor, Clovis Oncology, Li Auto, or Rigel Pharmaceuticals? PR Newswire NEW YORK, June 22, 2022 NEW YORK , June 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, F, CLVS, LI, and RIGL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. EFOI:...

Thinking about buying stock in Clovis Oncology, Revlon, Sundial Growers, Xpeng, or Bitnile? PR Newswire NEW YORK, June 15, 2022 NEW YORK , June 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, REV, SNDL, XPEV, and NILE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CLVS:...

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 ( 177 Lu-FAP-2286). Overall, in nine patients treated in the first two dose cohorts, 177 Lu-FAP-2286 demonstrated a manageable safety profile and...

Thinking about buying stock in Clovis Oncology, Houston American Energy, Soleno Therapeutics, SeaChange International, or Norwegian Cruise Line? PR Newswire NEW YORK, June 14, 2022 NEW YORK , June 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, HUSA, SLNO, SEAC, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CLVS:...

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the first presentation of data from the monotherapy arm of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO) as a late-breaking oral abstract (LBA5500) to be presented on Monday, June 6, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data demonstrate that Rubraca as first-line maintenance treatment significantly improved investigator-assessed progression-free survival (PFS)...